TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.

Genovefa A Papanicolaou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.